Understanding DEA Orders to Show Cause for Medical Cannabis Applicants

A medical cannabis business may have legitimate arguments against the DEA’s position. But preserving the opportunity to make those arguments requires responding correctly and on time.

This article addresses medical cannabis DEA registration applicants generally. The patient-documentation analysis uses a California dispensary as an example, with a comparison of how patient-certification pathways in D.C. and Minnesota may shape an applicant’s response. Manufacturers, distributors, and dispensers also need to address the requirements specific to the registration they are seeking.

On November 4, the DEA published a technical amendment clarifying a rule under which failing to respond to certain application-related correspondence results in the application being treated as withdrawn. Separately, recent reporting indicates that the DEA has issued orders to show cause to medical cannabis applicants in multiple jurisdictions, including California. DEA technical amendment, 91 FR 69500 (Nov. 4, 2026) · Marijuana Moment, Nov. 11, 2026

Different response rules govern application correspondence and an order to show cause.

What the DEA clarified about application withdrawal

Under 21 CFR § 1301.16(b), after an application has been accepted for filing, failing to respond to official correspondence concerning that application, sent by registered or certified mail with return receipt requested, is deemed a withdrawal of the application. The November 4 amendment expressly clarifies that this provision applies to both initial registration applications and renewal applications. The DEA describes the amendment as technical and consistent with its longstanding interpretation, not a new substantive requirement. 21 CFR § 1301.16 · DEA technical amendment, 91 FR 69500 (Nov. 4, 2026)

An unanswered email or missed telephone call does not, by itself, trigger withdrawal under this provision. Review each communication for other applicable response requirements.

An order to show cause is different

An order to show cause, or OSC, proposing to deny an application is not itself a final denial. It initiates a process through which the applicant can contest the DEA’s proposed action. 21 CFR § 1301.37

Under 21 CFR § 1301.37(d), an applicant seeking a hearing generally must file a hearing request with the DEA’s Office of Administrative Law Judges and serve the DEA no later than 30 days following receipt of the OSC.

The applicant must also file and serve an answer within that period. The answer must address each factual allegation by admitting it, denying it, or stating that the applicant lacks and cannot obtain sufficient information to admit or deny it. Factual allegations not denied are deemed admitted. 21 CFR § 1301.37 · 21 CFR § 1316.47

Under 21 CFR § 1301.43, failing to timely request a hearing or file the required answer can result in default. Unless excused, default waives the hearing right and admits the OSC’s factual allegations. The DEA may then seek a default final order. Limited good-cause relief exists, but businesses should not plan around obtaining it. That is different from an application simply being treated as withdrawn. 21 CFR § 1301.43

After receiving an OSC, an applicant needs the Administrator’s permission to voluntarily withdraw or amend its application. 21 CFR § 1301.16(a)

Preserve your response rights before arguing the merits

On November 11, Marijuana Moment reported that the DEA had sent OSCs to applicants in several jurisdictions, including California. Published excerpts from a California order challenge aspects of the state’s patient-documentation framework and its relationship to federal certification requirements. This discussion relies on that reporting, not an independent review of the complete California order. Marijuana Moment, Nov. 11, 2026

An applicant must still respond to its own OSC. It should not assume that disagreeing with the DEA’s interpretation, contacting its state regulator, or waiting for a broader industry response substitutes for responding to its own OSC.

Federal law also provides an opportunity to submit a corrective action plan. But applicants should not assume that submitting a plan or engaging in informal discussions extends the separate hearing-request or answer deadline. Those requirements need to be addressed independently. The immediate task is to understand what the DEA is proposing, identify the applicable deadlines, and preserve the available response options. 21 CFR § 1301.37 · 21 U.S.C. § 824(c)

What if the DEA is challenging the state program rather than your business?

An allegation that state law permits a practice is not necessarily evidence that the applicant engages in that practice or proposes to do so.

The DEA must explain the factual and legal basis for its proposed action. But an objection is not automatically invalid because it affects multiple applicants. The response should address how the alleged problem relates to this business, its license, and the activities it proposes to conduct. 21 CFR § 1301.37(a), (c)

Applicants should determine whether their own operating procedures can address the concern, or whether the DEA is asserting a licensing defect that requires a change to the state program. Applicants should explain what they actually do, what they propose to change, and why those practices satisfy the applicable requirements.

The published OSC excerpts also invoke U.S. obligations under the Single Convention on Narcotic Drugs, including its medical-prescription requirement. The federal registration rule requires DEA to consider public-interest factors and that treaty while also accepting qualifying state certifications or other documents under § 1301.13(k)(5). Applicants need to address the specific treaty objection raised in their OSC along with their own documentation practices. Marijuana Moment, Nov. 11, 2026 · 21 CFR § 1301.13(k), (k)(5), published at 91 FR 22722

Could requiring compliant medical documentation resolve the objection?

It may address the documentation issue. Under 21 CFR § 1301.13(k)(5), a certification or other document that state law deems sufficient for medical access “shall be sufficient” to permit dispensing when the federal conditions are met. Those conditions include the required date and signature, the patient’s full name and address, and the authorized practitioner’s name, address, and state license number. 21 CFR § 1301.13(k)(5)

My reading is that this gives an applicant a basis to explain how its own documentation practices meet the federal rule, even if the state permits other pathways. The response should show which documents the business will accept and how it will prevent dispensing when the requirements are not met.

California: what § 15404(b) requires and what the federal rule adds

California already requires a valid physician’s recommendation for medicinal retail sales under 4 CCR § 15404(b). The retailer must confirm the customer’s age, identity, and recommendation. An assertion that California simply makes recommendations optional for these sales would need to account for that rule. 4 CCR § 15404(b)

Section 15404(b) requires the recommendation, but does not itself specify every item the federal rule requires on the document. Under 21 CFR § 1301.13(k)(5), the document must be dated and signed on the day it is issued, include the patient’s full name and address, and contain the authorized signing practitioner’s name, address, and state license number. Compliance with California’s recommendation requirement therefore does not automatically establish compliance with the federal documentation standard. 4 CCR § 15404(b) · 21 CFR § 1301.13(k)(5)

In the California OSC excerpts published by Marijuana Moment, the DEA focuses on the documentation accepted for the state’s medical identification-card program and the fact that CDPH Form 9044 is optional. The agency argues that California does not require a written certification meeting § 1301.13(k)(5), and uses that asserted gap to challenge registration under the state program. Those excerpts do not establish that a particular applicant’s patient documents were reviewed and found deficient. Marijuana Moment, Nov. 11, 2026

A recommendation accepted under state law may still lack information required by the federal rule. For example, the published CDPH Form 9044 includes the patient’s name and physician information but has no designated field for the patient’s address, which the federal rule requires on the document. The actual document must be checked against every federal requirement. CDPH Form 9044 · 21 CFR § 1301.13(k)(5)

Making a particular form optional does not, by itself, make the recommendation optional or establish that every alternative document is inadequate. The federal rule accepts a certification or other qualifying document. A California applicant could therefore show that the documents it will require satisfy every federal condition and explain how staff will verify them. That supports a response to the documentation objection; whether it resolves the application also depends on the DEA’s remaining grounds for denial.

How responses may differ in D.C. and Minnesota

The distinction is the ability to obtain medical cannabis without a practitioner certification, rather than whether a particular state form is mandatory. D.C. law permits people 21 and older to self-certify that they are using cannabis for medical purposes instead of obtaining the signed practitioner recommendation otherwise required. Minnesota has a narrower alternative certification pathway for veterans; its enrollment guidance expressly permits a veteran’s self-certification in place of a health care practitioner’s certification. These are different pathways, not a universal self-certification requirement for every patient in both jurisdictions. D.C. Code § 7-1671.02(c)(1)(A) · Minn. Stat. § 342.52, subds. 2–3 · Minnesota OCM, How to Become a Patient

A patient’s self-certification alone does not supply the practitioner’s signature and information required by the federal rule. An applicant’s response should identify which patient-qualification pathway it uses and explain how it obtains and verifies the documentation required for federal dispensing. In California, the discussion may focus on whether an already-required recommendation contains every federal element. In D.C. or Minnesota, it may also address how the applicant’s practices relate to the available self-certification pathways. 21 CFR § 1301.13(k)(5)

These differences can lead applicants to present different arguments and evidence. The response should be tailored to the applicant’s state authorization, actual practices, and the grounds stated in its OSC. Any proposed documentation procedure must satisfy both state and federal law and address any separate licensing or treaty objection.

Support the response with operating procedures and evidence

The response should include:

• A document checklist covering every requirement in § 1301.13(k)(5).
• Written procedures and transaction controls that prevent dispensing when required documentation is missing, supported by staff training and appropriate verification records.
• A separate response to each remaining ground for denial, including any allegations involving adult-use activity, the scope of the state license, products, or supply-chain relationships.

Whether a proposed change resolves the OSC depends on the grounds the DEA has raised and the facts of the application. Applicants should support the proposed change with evidence and meet the separate response deadlines.

Losing pending status can have consequences beyond the application

The DEA’s medical marijuana guidance explains that qualifying timely applicants may conduct covered activities while their applications remain pending, subject to the applicable conditions. That category requires a completed application and fee payment during the April 28 to June 26, 2026 window, continued application pendency, and the requisite state medical marijuana license. The DEA excludes applicants whose applications have been withdrawn or finally denied. DEA, Medical Marijuana Timely Applicant Information · DEA medical marijuana information page

An OSC proposing denial is not the same as a final denial. But a withdrawal or final denial can eliminate the basis for relying on the pending-application provision.

Preparing the response

For medical cannabis businesses pursuing DEA registration, I would designate someone to monitor agency correspondence, preserve the documents and delivery records, and immediately route substantive notices to the person handling the application. For an OSC, review the actual document’s filing and service instructions. Do not assume that a phone call, an explanatory email, or a response sent to the wrong office preserves the right to a hearing.

Once those rights are preserved, the response should also address the merits: identify each alleged defect, show how it relates to the applicant, and support any proposed correction with evidence. An objection to a state’s rules and an objection to this applicant’s operation may call for different responses.

Frequently asked questions about medical cannabis DEA orders to show cause

Does an order to show cause mean my DEA application has already been denied?

No. An OSC proposing denial gives the applicant an opportunity to contest that proposed action. It is not itself a final denial, but it triggers response requirements that should be addressed immediately. 21 CFR § 1301.37

How long do I have to respond, and is a hearing request enough?

An applicant seeking a hearing generally must file and serve both a hearing request and an answer within 30 days following receipt of the OSC. A hearing request alone does not satisfy both requirements. Review the actual order’s filing and service instructions. 21 CFR § 1301.37(d)

Can I submit a corrective action plan instead?

Do not assume a corrective action plan replaces the hearing request and answer or extends their deadlines. A proposed correction and the filings needed to preserve a hearing should be addressed separately. 21 U.S.C. § 824(c) · 21 CFR § 1301.37(d)

What if the DEA’s objection concerns my state’s program?

The response should explain how the objection relates to your business and whether your own practices address it. State permission to engage in a practice does not necessarily mean you engage in it. But some licensing objections can affect multiple applicants, so individual operating changes may not resolve every issue.

If § 15404(b) already requires a physician’s recommendation, what is the federal issue?

Section 15404(b) already requires a valid physician’s recommendation for medicinal retail sales. The separate issue is whether the document includes everything required by 21 CFR § 1301.13(k)(5). For example, a recommendation missing the patient’s address would not satisfy that federal requirement. An applicant can address this by showing that every document it will accept meets both standards, while separately responding to any broader licensing objections. 4 CCR § 15404(b) · 21 CFR § 1301.13(k)(5)

How might responses differ among California, D.C., and Minnesota?

California requires physician recommendations for medicinal retail sales. D.C. permits self-certification for people 21 and older, while Minnesota offers an alternative certification pathway for veterans. Those differences can shape the arguments and evidence an applicant presents. The response should explain which pathway the business uses and how its documentation and dispensing controls satisfy federal requirements. 4 CCR § 15404(b) · D.C. Code § 7-1671.02(c) · Minn. Stat. § 342.52, subd. 3 · 21 CFR § 1301.13(k)(5)

Attorney advertising. General information only, not legal advice. Response requirements depend on the document, service or receipt, and applicable law. Reading this article does not create an attorney-client relationship.